Evidence map›Paper›PMID 29976104›Full record

ReviewExpert review of cardiovascular therapy2018

Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction.

Gilman D Plitt, Jordan T Spring, Michael J Moulton, Devendra K Agrawal

Abstract readReview
In one paragraph

Review in Expert review of cardiovascular therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gilman D Plitta Department of Clinical & Translational Science , Creighton University School of Medicine , Omaha , NE , USA.
Jordan T Springa Department of Clinical & Translational Science , Creighton University School of Medicine , Omaha , NE , USA.
Michael J Moultonb Department of Cardiothoracic Surgery , University of Nebraska Medical Center , Omaha , NE , USA.
Devendra K Agrawala Department of Clinical & Translational Science , Creighton University School of Medicine , Omaha , NE , USA.ORCID http://orcid.org/0000-0001-5445-0013
Creighton University · USUniversity of Nebraska Medical Center · US

Funding

MESENCHYMAL STEM CELLS IN THE PREVENTION OF THROMBOSIS AND NEOINTIMAL HYPERPLASIAR01HL112597 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2012 to 2016
$3.8M
EPICARDIAL ADIPOSE TISSUE, OBESITY AND INFLAMMATION IN ATHEROSCLEROSISR01HL120659 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2013 to 2017
$3.6M
VITAMIN D AND IMMUNOMODULATION IN CORONARY ARTERY DISEASER01HL116042 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2012 to 2016
$3.3M
GENE AND STEM CELL THERAPY IN CORONARY ARTERY BYPASS GRAFTR01HL128063 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2015 to 2018
$2.9M
NHLBI NIH HHS R01 HL112597NHLBI NIH HHS R01 HL116042NHLBI NIH HHS R01 HL120659NHLBI NIH HHS R01 HL128063
6 · The paper itself

Abstract

introductionHeart failure with preserved ejection fraction (HFpEF) continues to be a major challenge for clinicians. Many crucial aspects of the syndrome remain unclear, including the exact pathophysiology, early diagnosis, and treatment. Patients with HFpEF are often asymptomatic late into the disease process, and treatment with medications commonly used in heart failure with reduced ejection fraction (HFrEF) has not been proven to be beneficial. In addition, the confusion of similar terms with HFpEF, such as diastolic heart failure, and diastolic dysfunction (DD), has led to a misunderstanding of the true scope of HFpEF. Areas covered: In this review, authors highlight the differences in terminology and critically review the current knowledge on the underlying mechanisms, diagnosis, and latest treatment strategies of HFpEF. Expert commentary: While significant advances have been made in the understanding of HFpEF, the definitive diagnosis of HFpEF continues to be difficult. The development of improved and standardized methods for detecting DD has shown promise in identifying early HFpEF. However, even with early detection, there are few treatment options shown to provide mortality benefit warranting further investigation.

Indexed as

Heart FailureHumansStroke VolumeBiomarkersDiastolic dysfunctionHFpEFHFrEFInflammation

Identifiers

PMID29976104
PMCPMC6287909
OpenAlexW2850636599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.